Clinical trials: sponsored by Daiichi Sankyo
Ovarian Cancer, Ovarian Neoplasms
A Study of Raludotatug Deruxtecan With or Without Bevacizumab as First-Line Maintenance Treatment in Non-HRD-Positive Advanced Ovarian Cancer (MK-5909-006, (ENGOT-ov102/GOG-3141/ REJOICE-Ovarian 04)
Researchers are looking for new ways to treat ovarian cancer (OC). Current treatment for OC may start with surgery to remove as much of the cancer as possible. After surgery, people may receive chemotherapy.
- Conditions
- Ovarian Cancer, Ovarian Neoplasms, Peritoneal Cancer, Fallopian Tube Cancer
- Trial name
- NCT07776691
- Testing
- R-DXd, Bevacizumab
- Where
- 11 sites in United States, Israel and 2 more
- Volunteers
- 802 people
- Sponsor
- Merck Sharp & Dohme LLC
Carcinoma, Non-Small-Cell Lung
KEYMAKER-U01 Substudy 01A: Efficacy and Safety Study of Pembrolizumab (MK-3475) With or Without Chemotherapy When Used With Investigational Agents in Treatment-naïve Participants With Stage IV Non-small Cell Lung Cancer (NSCLC) (MK-3475-01A/KEYMAKER-U01A)
The purpose of this study is to assess the efficacy and safety of pembrolizumab (MK-3475) with or without chemotherapy in combination with vibostolimab (MK-7684), boserolimab (MK-5890), MK-4830, MK-0482, I-DXd, or HER3-DXd in…
- Trial name
- NCT04165070
- Testing
- Pembrolizumab, Carboplatin, Paclitaxel
- Where
- 47 sites in United States, Canada and 8 more
- Volunteers
- 450 people
- Sponsor
- Merck Sharp & Dohme LLC
Carcinoma, Non-Small-Cell Lung
KEYMAKER-U01 Umbrella Master Study: Studies of Investigational Agents With Either Pembrolizumab (MK-3475) Alone or With Pembrolizumab PLUS Chemotherapy in Participants With Non-small Cell Lung Cancer (NSCLC) (MK-3475-U01/KEYMAKER-U01)
This study is referred to as the "umbrella master protocol" for pembrolizumab (MK-3475) in the treatment of non-small cell lung cancer (NSCLC).
- Trial name
- NCT04165798
- Testing
- Tumor Imaging, Tumor Tissue Collection, Blood Sample Collection
- Where
- 48 sites in United States, Canada and 8 more
- Volunteers
- 1,065 people
- Sponsor
- Merck Sharp & Dohme LLC
Stomatitis
An Open-label, Single-arm Study of Prophylaxis for Datopotamab Deruxtecan (Dato-DXd) -Related Stomatitis in Eligible Patients With Metastatic or Inoperable Locally Recurrent Breast Cancer or Locally Advanced or Metastatic Epidermal Growth Factor Receptor-Mutated Non-small Cell Lung Cancer.
This is a multicenter, open-label, single-arm study of prophylaxis for Dato-DXd-related stomatitis in eligible patients with metastatic or inoperable locally recurrent breast cancer or locally advanced or metastatic Epidermal…
- Trial name
- TROPION-SWISH (NCT07357597)
- Testing
- Dexamethasone mouthwash, Datopotamab Deruxtecan (Dato-DXd)
- Where
- 41 sites in United States
- Volunteers
- 100 people
- Sponsor
- AstraZeneca
Ovarian Cancer
Study of Trastuzumab Deruxtecan With Bevacizumab Versus Bevacizumab Monotherapy for First-line Maintenance in HER2-Expressing Ovarian Cancer (DESTINY-Ovarian01)
This clinical trial is designed to evaluate the efficacy and safety of T-DXd in combination with bevacizumab versus bevacizumab monotherapy as first-line maintenance therapy, in participants with human epidermal growth factor 2…
- Trial name
- DO-01 (NCT06819007)
- Testing
- Trastuzumab Deruxtecan, Bevacizumab
- Where
- 232 sites in United States, Australia and 24 more
- Volunteers
- 582 people
- Sponsor
- Daiichi Sankyo
Non-Small Cell Lung Cancer
Phase III, Open-label, Study of First-line Dato-DXd in Combination With Rilvegostomig for Advanced Non-squamous NSCLC With High PD-L1 Expression (TC ≥ 50%) and Without Actionable Genomic Alterations
The purpose of this study is to evaluate efficacy and safety of Dato-DXd in combination with rilvegostomig or rilvegostomig monotherapy compared with pembrolizumab monotherapy as a first line therapy in participants with locally…
- Trial name
- TROPION-Lung10 (NCT06357533)
- Testing
- Datopotamab Deruxtecan, Rilvegostomig, Pembrolizumab
- Where
- 290 sites in United States, Australia and 19 more
- Volunteers
- 675 people
- Sponsor
- AstraZeneca
Solid Tumor, Locally Advanced Non-Small Cell Lung Cancer
A Study of DS-3939a in Participants With Solid Tumors
The primary purpose of the study is to evaluate the safety, tolerability, and efficacy of DS-3939a in combination with other anticancer agents or as a monotherapy in participants with solid tumors.
- Conditions
- Solid Tumor, Locally Advanced Non-Small Cell Lung Cancer, Metastatic Non-Small Cell Lung Cancer
- Trial name
- NCT07739966
- Testing
- DS-3939a, Pembrolizumab, Carboplatin
- Where
- 76 sites in United States, Argentina and 11 more
- Volunteers
- 400 people
- Sponsor
- Daiichi Sankyo
Endometrial Cancer
A Study of Trastuzumab Deruxtecan Versus Standard of Care Chemotherapy for HER2-Expressing (IHC 3+/2+) Endometrial Cancer in Adjuvant Setting
This study is designed to assess efficacy and safety of T-DXd adjuvant therapy, with or without radiotherapy, post-surgery in anticancer treatment naïve (including neoadjuvant therapy) endometrial cancer with various HER2…
- Trial name
- NCT07022483
- Testing
- Trastuzumab Deruxtecan, Chemotherapy
- Where
- 86 sites in United States, Argentina and 13 more
- Volunteers
- 710 people
- Sponsor
- Daiichi Sankyo
Esophageal Squamous Cell Carcinoma
Substudy 06E: Umbrella Study of Combination Therapies in Esophageal Cancer (MK-3475-06E/KEYMAKER-U06)
Researchers are looking for new ways to treat esophageal squamous cell carcinoma (ESCC). ESCC is a type of cancer that starts in certain cells that line the esophagus.
- Trial name
- NCT06780111
- Testing
- Pembrolizumab, I-DXd, Leucovorin
- Where
- 52 sites in United States, Brazil and 14 more
- Volunteers
- 298 people
- Sponsor
- Merck Sharp & Dohme LLC
Advanced or Metastatic NSCLC
Phase 1b Study of Dato-DXd in Combination With Immunotherapy With or Without Carboplatin in Advanced or Metastatic Non-Small Cell Lung Cancer
This study will assess safety, tolerability, and treatment activity of datopotamab deruxtecan (Dato-DXd) in combination with immunotherapy with or without carboplatin in participants with advanced or metastatic non-small cell…
- Trial name
- TROPION-Lung04 (NCT04612751)
- Testing
- Datopotamab deruxtecan, Durvalumab, Carboplatin
- Where
- 42 sites in United States, Belgium and 6 more
- Volunteers
- 155 people
- Sponsor
- AstraZeneca
Carcinoma, Non-Small-Cell Lung
A Study of Investigational Agents in Participants With Previously Treated Stage IV Nonsquamous Non-small Cell Lung Cancer (NSCLC) (MK-3475-01H/KEYMAKER-U01)
Researchers are looking for new ways to treat metastatic nonsquamous non-small cell lung cancer (NSCLC) that has been treated before. Metastatic means the cancer has spread to other parts of the body.
- Trial name
- NCT06780085
- Testing
- Raludotatug Deruxtecan, Ifinatamab Deruxtecan, Docetetaxel
- Where
- 36 sites in United States, Chile and 8 more
- Volunteers
- 96 people
- Sponsor
- Merck Sharp & Dohme LLC
Solid Cancer
A Study of Raludotatug Deruxtecan (R-DXd) in Subjects With Platinum-resistant, High-grade Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
This study will evaluate the safety and efficacy of R-DXd therapy in participants with ovarian, peritoneal, or fallopian tube cancer.
- Trial name
- NCT06161025
- Testing
- R-DXd, Paclitaxel, Topotecan
- Where
- 167 sites in United States, Australia and 17 more
- Volunteers
- 860 people
- Sponsor
- Daiichi Sankyo
Non-Small Cell Lung Cancer (NSCLC)
U3-1402 in Metastatic or Unresectable Non-Small Cell Lung Cancer
This study was designed to evaluate safety and antitumor activity of HER3-DXd in two parts: Dose Escalation and Dose Expansion. In Dose Escalation, HER3-DXd was evaluated in participants with metastatic or unresectable NSCLC with…
- Trial name
- NCT03260491
- Testing
- HER3-DXd (FL-DP), HER3-DXd (CTM-1 Lyo-DP), HER3-DXd (CTM-3 Lyo-DP)
- Where
- 37 sites in United States, Japan and 4 more
- Volunteers
- 312 people
- Sponsor
- Daiichi Sankyo
Metastatic Castration-resistant Prostate Cancer
A Study of Valemetostat (DS-3201b) in Combination With Darolutamide in Metastatic Castration Resistant Prostate Cancer (mCRPC)
This study will assess the safety and tolerability of valemetostat in combination with darolutamide in participants with Metastatic Castration Resistant Prostate Cancer (mCRPC).
- Trial name
- NCT07244341
- Testing
- Valemetostat, Darolutamide
- Where
- 29 sites in United States, Australia and 5 more
- Volunteers
- 60 people
- Sponsor
- Daiichi Sankyo
Advanced Cancer, Metastatic Cancer
A Study to Provide Continued Access to and Assess Long-Term Safety of the Study Drug(s)
This open-label, multicenter, rollover study will provide continued treatment for participants deriving benefit from different therapies received in studies sponsored by Daiichi Sankyo, Inc.
- Trial name
- NCT06174987
- Testing
- T-DXd
- Where
- 34 sites in United States, Australia and 11 more
- Volunteers
- 75 people
- Sponsor
- Daiichi Sankyo
Non-Small Cell Lung Cancer (NSCLC)
HER3-DXd (Patritumab Deruxtecan; U3-1402) in Combination With Osimertinib in Subjects With Locally Advanced or Metastatic EGFR-mutated Non-Small Cell Lung Cancer
This study includes a Dose Escalation Part to identify the recommended combination dose (RCD) and a Dose Expansion Part to further evaluate efficacy and safety.
- Trial name
- NCT04676477
- Testing
- HER3-DXd, Osimertinib
- Where
- 31 sites in United States, Japan and 2 more
- Volunteers
- 246 people
- Sponsor
- Daiichi Sankyo
Esophageal Squamous Cell Carcinoma
A Study of Ifinatamab Deruxtecan in Subjects With Pretreated Advanced or Metastatic Esophageal Squamous Cell Carcinoma (ESCC) (IDeate-Esophageal01)
This study is designed to assess the efficacy and safety of ifinatamab deruxtecan (I-DXd) in patients with unresectable advanced or metastatic esophageal squamous cell carcinoma (ESCC) who have experienced disease progression…
- Trial name
- NCT06644781
- Testing
- Ifinatamab deruxtecan, Docetaxel, Paclitaxel
- Where
- 168 sites in United States, Belgium and 15 more
- Volunteers
- 510 people
- Sponsor
- Daiichi Sankyo
Advanced Solid Tumor
A Study of DS-1103a Combination Therapy in Participants With Advanced Solid Tumors
This study will evaluate the safety and efficacy of DS-1103a combination therapy in participants with advanced solid tumors.
- Trial name
- NCT05765851
- Testing
- DS-1103a, T-DXd
- Where
- 15 sites in United States, Canada and 4 more
- Volunteers
- 128 people
- Sponsor
- Daiichi Sankyo
Recurrent or Metastatic Solid Tumors
A Study to Evaluate the Efficacy and Safety of Ifinatamab Deruxtecan (I-DXd) in Subjects With Recurrent or Metastatic Solid Tumors (IDeate-PanTumor02)
This study is designed to assess the efficacy and safety of ifinatamab deruxtecan (I-DXD) in the following tumor types: endometrial cancer (EC); head and neck squamous cell carcinoma (HNSCC); pancreatic ductal adenocarcinoma…
- Trial name
- NCT06330064
- Testing
- Ifinatamab deruxtecan
- Where
- 120 sites in United States, Argentina and 16 more
- Volunteers
- 680 people
- Sponsor
- Daiichi Sankyo
Advanced Solid Tumor, Melanoma
A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors
This is a proof-of-concept study designed to investigate HER3-DXd monotherapy in locally advanced unresectable or metastatic solid tumors.
- Conditions
- Advanced Solid Tumor, Melanoma, Head and Neck Cancer, Gastric Cancer
- Trial name
- NCT06172478
- Testing
- HER3-DXd
- Where
- 96 sites in United States, Australia and 14 more
- Volunteers
- 740 people
- Sponsor
- Daiichi Sankyo